For example, drugs targeting EGFR (epidermal growth factor receptor), especially the EGFRvIII variant, such as afatinib, which gave interesting in vitro and in silico results [104,105], dacomitinib, studied both in vitro and in mice models [106], and erlotinib, whose possible therapeutic interest has been validated in silico, have shown limited success [107]—likely due to tumor heterogeneity and resistance mechanisms—or have not yet moved to more advanced stage studies. Here, EGFR is linked to neoplasm.